Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 02, 16:00
Forte Biosciences Research and Development Expense (Annual) : 58.25M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 58.25M |
| December 31, 2024 | 21.19M |
| December 31, 2023 | 21.86M |
| December 31, 2022 | 5.594M |
| December 31, 2021 | 13.82M |
| December 31, 2020 | 9.95M |
| Date | Value |
|---|---|
| December 31, 2019 | 2.673M |
| December 31, 2018 | 50.46M |
| December 31, 2017 | 29.11M |
| December 31, 2016 | 27.22M |
| December 31, 2015 | 19.17M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| argenx SE | 1.356B |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |